Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500574 · ClinicalTrials.gov registry record · Phase 1
Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension
A Phase 1 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04500574: Clinical Trial Phase 1 study, sponsored by Massachusetts Eye and Ear Infirmary.
NCT04500574 is a Phase 1 study that was terminated before completion, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04500574, a Phase 1 study, was terminated before completion, sponsored by Massachusetts Eye and Ear Infirmary.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
In this research study, we will assess the safety, tolerability, comfort, and feasibility of lowering intraocular pressure using a novel Contact Lens Drug Delivery System with latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for decades. Currently, latanoprost is FDA-approved to be administered to patients as eye drops, but using eye drops has challenges (having to remember to take the drop, getting the drop in the eye). This clinical trial is being done to determine the safety, tolerability, and effectiveness of using latanoprost to deliver latanoprost in a new way (through a drug-eluting contact lens). The study includes two phases. Phase A is intended to assess safety and tolerability and Phase B to assess safety and effectiveness.
Primary Outcome
Safety assessed by the occurrence of the following adverse events: ocular infection, corneal epithelial defects or signs of corneal toxicity that are not contact lens staining patterns, superficial punctate or vortex, cystoid macular edema
Interventions
- DRUG Latanoprost eluting contact lens
- DRUG Topical Latanoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2025-10-10 |
| Phase | Phase 1 |
Why NCT04500574 stopped before completion
NCT04500574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Latanoprost eluting contact lens is the first listed.
NCT04500574 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04500574 about?
NCT04500574 is a clinical study titled "Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension". In this research study, we will assess the safety, tolerability, comfort, and feasibility of lowering intraocular pressure using a novel Contact Lens Drug Delivery System with latanoprost. Latanoprost is a well-studied medication and has been used to treat glaucoma for decades. Currently, latanopros...
What is the current status of trial NCT04500574?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-04-03. Estimated completion is 2025-10-10.
What interventions are being tested in trial NCT04500574?
The interventions under investigation include: Latanoprost eluting contact lens (DRUG), Topical Latanoprost (DRUG).
Who is sponsoring clinical trial NCT04500574?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04500574's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI